Innovator Spotlight

Celebrating the rich technologies UC San Diego brings to market.

Mathieu Bakhoum, Associate Physician, Ophthalmology, UC San Diego Health

Highlighted Technology: Detecting cardiovascular disease using noninvasive imaging of the eye

Please explain your technology.

Heart Disease and stroke are the leading cause of death worldwide. They are also very common, and much more so, in older individuals. Unfortunately, many individuals are unaware that they have an underlying cardiovascular disease until they are impacted by a catastrophic event such as a stroke, a heart attack or dementia. Fortunately, early detection can lead to lifestyle modifications and better medical and surgical management that can alter the course of the disease and reduce mortality.

There are many causes of cardiovascular disease. Hence, screening for cardiovascular disease in asymptomatic individuals using a myriad of diagnostic tests would be costly and challenging. The eyes are a window into our health, and many systemic diseases can manifest in the eye. Cardiovascular disease is no exception.

I am a physician scientist and a retina surgeon. In my clinical practice, I identified that ischemic lesions or ‘mini-strokes’ in the eye are present in individuals with cardiovascular disease.

What are the advantages of this technology over the current state-of-the art?

There are many advantages of this technology. These retinal ischemic perivascular lesions, or ‘RIPLs’, can be identified from standard optical coherence tomography (OCT) scans. The eye scan (or OCT) is non-invasive, does not involve any ionizing radiation and is already clinically approved. It can also be performed under two minutes. Our technology establishes the clinical utility of RIPLs in detecting cardiovascular disease. It also demonstrates a feasible and reproducible way to consistently identify RIPLs from regular OCT scans.

What is the next step to get this diagnostic test in the clinic?

Our test relies on OCT scans which are already in widespread use in eye clinics. Our technology aims to identify these lesions using a simple and methodical protocol. Our next goal is to demonstrate the utility of RIPLs in prospective studies, as a screening tool for the general population.

thumbnail_Profile UCSD

We are looking for companies interested in licensing & commercializing this technology.

Please contact licensing officer Devora Rossi at drossi@ucsd.edu or Mathieu Bakhoum at mbakhoum@health.ucsd.edu.

For licensing or commercialization questions, please contact Devora Rossi, Ph.D. (drossi@ucsd.edu), Senior Innovation & Commercialization Manager.  

. . . . . .
Rossi's background is in Immunology and she has several years of experience in Business Development in various biotech companies before coming to UC San Diego.